Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Invested Capital (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Invested Capital for 15 consecutive years, with $2.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital rose 2.9% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Sep 2025, up 2.9%, and an annual FY2024 reading of $2.1 million, down 67.29% over the prior year.
  • Invested Capital was $2.8 million for Q3 2025 at Alaunos Therapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $105.6 million in Q1 2021 and bottomed at $1.1 million in Q1 2025.
  • Average Invested Capital over 5 years is $37.9 million, with a median of $21.6 million recorded in 2023.
  • The sharpest move saw Invested Capital crashed 88.6% in 2023, then increased 2.9% in 2025.
  • Year by year, Invested Capital stood at $82.2 million in 2021, then plummeted by 32.68% to $55.3 million in 2022, then plummeted by 88.6% to $6.3 million in 2023, then plummeted by 67.29% to $2.1 million in 2024, then skyrocketed by 35.87% to $2.8 million in 2025.
  • Business Quant data shows Invested Capital for TCRT at $2.8 million in Q3 2025, $3.7 million in Q2 2025, and $1.1 million in Q1 2025.